DKK1 and neoplasm: Next, we administered the DKK1-neutralizing monoclonal antibody mDKN01 (10mg/kg), every other day following tumor inoculation and found a significant reduction in primary tumor growth compared to isotype control (IgG) (Fig. 1B).